Ryan Goodland’s Post

The field of cardiovascular medicine is rapidly evolving, with researchers exploring innovative treatment approaches to address complex heart and vascular conditions. Novel therapies leveraging gene editing, stem cell technologies, and regenerative medicine techniques hold promise for targeting the fundamental mechanisms of diseases like heart failure, atherosclerosis, and arrhythmias. These emerging strategies aim to improve patient outcomes and quality of life beyond what is possible with current standard-of-care interventions.  What are the most exciting or promising emerging therapeutic strategies in cardiovascular diseases? Share your thoughts with us down below. #CardiovascularMedicine #InnovativeTherapies #RegenerativeTreatments #FutureOfHeartHealth

The recognition of miRNA’s role in gene regulation and its profound impact on aging, cell regulation, and senescence is a major step forward for the scientific community. This discovery brings us closer to understanding the mechanisms behind cellular aging and opens new doors for innovative therapies. As someone deeply involved in the field of stem cells and regenerative medicine, I believe this is just the beginning. Next year, we can expect even more focus on aging-related studies, and stem cell research especially iPSC will undoubtedly play a pivotal role. The intersection of miRNA, stem cells, and aging holds immense potential for revolutionizing treatments for age-related diseases and conditions. #NobelPrize #AgingResearch #StemCells #miRNA #RegenerativeMedicine

Stanford Medicine Children's #Health has recently introduced a gene therapy approved by the #FDA for X linked adrenoleukodystrophy (ALD) an severe neurological condition affecting children. The groundbreaking stem cell-based therapy is a more efficient option compared to the conventional stem cell transplantation. The treatment involves altering the patient's #stemcells to stop the advancement of #ALD, eliminating the risks linked to using donor cells like graft versus host disease (GVHD). What were the results of the #stemcelltherapy? It has helped the two children named "Ivan" and "Israel" are living normal kids life. They even indulge in various kid pastimes with their younger sister. Discover details about this transformative therapy. https://lnkd.in/g3WMSPzd

Celebrating the 2024 Nobel Prize for Groundbreaking Research on miRNAs! 🏆🔬 The 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for their discovery of microRNAs (miRNAs), which play a crucial role in regulating gene expression. Ambros first identified miRNA in C. elegans in 1993, while Ruvkun later discovered another miRNA and demonstrated its evolutionary importance. The 2024 Nobel Prize was awarded for pioneering research on microRNAs (miRNAs), small yet powerful molecules that regulate gene expression. This discovery has revolutionized our understanding of cellular processes and has opened new avenues for treating diseases like cancer, neurodegenerative disorders, and viral infections. By unveiling the critical role miRNAs play in gene regulation, this work is pushing the boundaries of medical science and personalized medicine! #NobelPrize2024 #miRNA #GeneTherapy #MedicalBreakthrough #Biotech

🌟 Just wrapped up an incredible two days at the Mass General Brigham Gene and Cell Therapy Symposium! 🌟 This experience was truly enlightening, showcasing groundbreaking advancements that could reshape how we approach treatment for a wide range of conditions. From innovative gene editing techniques to the latest in cellular therapies that are turning cold TME into 'hotbeds' of activated CTL & NK cells. The symposium highlighted the potential of these technologies to target diseases at their source and offer personalized treatment options.   💡 I had the privilege of learning from some of the greatest minds in the field, including Crystal Mackall, MD (Stanford University), Marcela Maus, MD, PhD, Jeff Karp, PhD, and Natalie Artzi, PhD. Each speaker brought a unique perspective, from groundbreaking advances in CAR-T cell therapies and gene therapy to innovative approaches in regenerative medicine and biomaterials. 🌡   The symposium also highlighted the collaborative spirit and commitment to innovation at Mass General Brigham, where researchers and clinicians are working hand-in-hand to move therapies from bench to bedside. 🏥   Additionally, a powerful fireside chat on patient advocacy underscored the importance of keeping patients at the center of all we do.   Huge thanks to the speakers, organizers, and researchers who shared their groundbreaking work 🙏 . I'm excited to carry these insights forward and apply them in my own!   #GeneTherapy #CellTherapy #ClinicalResearch #ClinicalTrials #ClinicalOperations #CRO #ClinicalResearchCareers #Oncology

April marks Parkinson's Awareness Month—a time to spotlight the second-most common neurodegenerative disorder that impacts millions of lives worldwide 🌍 Despite progress in the field, people living with Parkinson's face daily challenges and a range of symptoms that extend far beyond tremors. Though current treatments, such as dopamine replacement therapy and Deep Brain Stimulation (DBS), offer some hope, they are far from perfect 🔬 However, the future looks promising. From gene therapy to immunotherapy targeting alpha-synuclein aggregates and stem cell research, there is a potential for breakthroughs in the treatment of Parkinson's 🌟 This Parkinson's Awareness Month, let's commit to increasing our understanding and support for those affected by Parkinson's. By speaking up and speeding up research, we can pave the way towards a future where Parkinson's is but a memory 🕊️ #ParkinsonsAwarenessMonth | #ParkinsonsDisease | #MedicalResearch

If you're attending the 6th Annual Gene Therapy for CNS Summit in Boston, make sure attend our CEO Josefina Nilssons presentation at 10 am EST #TODAY! Or find her at the conference to talk about our GMP-certified TEM services, quality control analyses of nanoparticles, or simply to say hello. This year’s summit focuses on breaking barriers in gene therapy for neurological conditions, from novel AAV performance to improving biodistribution and translating these therapies from preclinical models to real-world clinical success. As a company committed to advancing treatments and we’re thrilled to be part of this conversation with leading experts in translational research, R&D, and clinical innovation. #GeneTherapy #Neurology #Innovation #Leadership #TEM #QuTEM

"The IPS-cell or Induced Pluripotent Stem-cell can possible can become therapeutic subject to study." Let's say, Transcription regulators are the majorly focused in current study of cell differentiation and regulation. However, it is experimentally found to regulate the cell differentiation even by induced artificial gene regulators/transcription factor. For example, Inducing the eye factors of Drosophila to somatic cell lead to eye like organ formation at the leg in larva stage. Even some of the master regulators such as, Oct4, Sox2, Klif4 etc. are cause to turnover somatic cell to intermediary IPS-cell. In fact, all of them are self activators and each other. Following up, the people with challenged by nerve or liver diseases, may be blessed with advanced study outcome of IPS-cell therapies. Ref: 1. Abou-Saleh, H., Zouein, F.A., El-Yazbi, A. et al. The march of pluripotent stem cells in cardiovascular regenerative medicine. Stem Cell Res Ther 9, 201 (2018). https://lnkd.in/gABbsrns 2. The Molecular Biology of the Cell. Bruce et al. #MolecularBiology #IPScell #Transcription #GeneRegulation #ResearchStudy

[ #aging #epigenetics #neurogenesis ] #TERT activation targets #DNA #methylation and multiple aging hallmarks Nice paper from DePinho et coll. in the journal Cell (Published June 21, 2024). The authors report the identification of a TERT activator compound (TAC) that upregulates TERT transcription via the MEK/ERK/AP-1 cascade. In the brain, TAC alleviates #neuroinflammation, increases neurotrophic factors, stimulates adult neurogenesis, and preserves cognitive function without evident toxicity, including cancer risk. As the authors say, "these findings underscore TERT’s critical role in aging processes and provide preclinical proof of concept for physiological TERT activation as a strategy to mitigate multiple aging hallmarks and associated pathologies." In a nutshell: ✔ TERT (telomerase reverse transcriptase) has been linked directly or indirectly to all hallmarks of aging ✔ TERT gene is epigenetically repressed with onset of aging markers in all tissues ✔ TAC (TERT activator compound) restores TERT levels to promote telomere maintenance and reprogram gene expression ✔ TAC in aged mice reduces #senescence / #inflammation and increases #neurogenesis / #cognition https://lnkd.in/d-iCF6-s

Join us at the Drug Discovery Biology Strategy Meeting this November 12th in Boston to hear from Anitha Krishnan, Ph.D, Executive Director of Research at Aviceda Therapeutics. Anitha brings over a decade of innovative scientific expertise in biochemical, immunological, and molecular biology techniques. Her work is pivotal in gene therapy and cell transplantation studies, targeting ocular diseases such as Glaucoma and Age-related Macular Degeneration. She has made significant strides in understanding immune responses in neurodegeneration and autoimmune diseases, particularly through her research on microglial and macrophages and the Fas-FasL system. Anitha will be delving into the "Opportunities and Risks in the Preclinical Development of Molecules that Do Not Cross React with Rodents," offering invaluable insights from her extensive experience in advancing therapeutic approaches from discovery through to clinical trials. Don't miss the opportunity to gain from her comprehensive expertise and her knack for leading innovative preclinical research. #DrugDiscovery #BiomedicalResearch #OcularDiseases #PreclinicalDevelopment #BostonEvents #LifeSciences #StrategyMeetings